Search Results for “EC” – Page 327 – media

Roche Jumps into Lucrative Weight-Loss Space with $2.7B Carmot Buy

By Tristan Manalac Pictured: Roche’s building in California Roche on Monday announced it has entered into a definitive merger agreement with Berkeley, California-based Carmot Therapeutics, a move that could place it in the thick of the lucrative and increasingly competitive weight-loss market. As per the terms of the acquisition, Roche will make an upfront payment of $2.7 billion at the transaction’s close, which the companies anticipate will occur in the first quarter of 2024, pending regulatory and anti-trust clearance. Carmot’s equity holders will also be eligible for up to $400 million in additional payments, contingent on the achievement of certain milestones. In return, Roche will gain access to Carmot’s portfolio of preclinical and clinical assets, including three GLP-1 receptor agonists, which have “best-in-class potential to treat obesity,” according to Monday’s news release. Carmot’s lead asset is CT-388, a dual agonist of both the GLP-1 and GIP receptors that is ready ...
- Source: drugdu
- 101
- December 6, 2023
EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results

By Connor Lynch Pictured: A patient being examined by an eye doctor EyePoint Pharmaceuticals marked a major win Monday, with Phase II results of its anti-VEGF therapy for wet age-related macular degeneration showing comparable results to Regeneron’s Eylea on a less-frequent dosing regimen. Share prices jumped over 200% in premarket trading on the news that EYP-1901 had hit all primary and secondary endpoints in the DAVIO 2 trial. The trial was investigating EyePoint’s EYP-1901 therapy, an “investigational sustained delivery maintenance treatment” for wet age-related macular degeneration (AMD) that combines vorolanib, a selective tyrosine kinase inhibitor, with “bioerodible Durasert E,” an injectable drug delivery system. The study tested two doses of the therapy, both 2 mg and 3 mg in 160 patients, finding both met all of the primary and secondary endpoints. That included the primary endpoint of “statistical non-inferiority change in best corrected visual acuity,” compared to the control of ...
- Source: drugdu
- 111
- December 6, 2023
Aledade, Anthem Form New Value-Based Medicaid Partnership for Virginians

Anthem Blue Cross and Blue Shield in Virginia has partnered with Aledade, a network of independent primary care practices, to improve access to value-based primary care for Medicaid members, the companies announced last week. Bethesda, Maryland-based Aledade helps independent practices, health centers and clinics engage in value-based care through data insights, policy expertise and contracting support. It works with more than 1,500 practices and community health centers across 46 states and the District of Columbia. Through the partnership, Anthem’s Medicaid members will have better access to primary and preventive care, including health screenings. Aledade and Anthem began working together last year with the insurer’s Medicare Advantage and commercially insured members. The partnership enables Aledade to bring value-based care — in which clinicians are paid based on the quality of care they deliver versus the volume of care they provide — to more than 80 practices, 15 health centers and 25 ...
- Source: drugdu
- 90
- December 6, 2023
GE HealthCare, AirStrip partner on patient monitoring, cardiac data visualization

BY SEAN WHOOLEY GE HealthCare (Nasdaq: GEHC)+ announced today that it entered into a joint commercialization agreement with AirStrip to distribute patient monitoring technology. AirStrip, a member of the Nantworks group of AI-driven companies, develops cardiology and patient monitoring solutions. These technologies offer data visualization technology through a proprietary, native mobile application. Clinicians can see clinical data on mobile devices and on the web with the AirStrip technology. Under the agreement, GE HealthCare now serves as the exclusive distributor of AirStrip cardiology and patient monitoring solutions in the U.S. The deal offers data visualization that healthcare systems can purchase together. GE HealthCare says that pairing its technology with AirStrip’s allows for remote collaboration. It enables clinicians to view patient data from a distance and view multiple patients on one screen by level of priority. The collaboration has a focus on streamlining and optimizing in-patient care solutions. “We are proud to ...
- Source: drugdu
- 91
- December 6, 2023
NEBGH Helps Employers Combat Cardiovascular Disease in Women Through New Guide

A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce. By MARISSA PLESCIA About 44% of women in the U.S. are living with a form of heart disease, and heart disease is the leading cause of death for women in the U.S. Making matters worse is the lack of knowledge about these stats: only 56% of women realize that heart disease is the number one killer for American women. Cardiovascular disease in the U.S. costs about $363 billion annually in direct and indirect costs (such as missed workdays). That’s why the Northeast Business Group on Health (NEBGH) released a free guide for employers on Thursday that is focused on cardiovascular disease, diabetes and obesity in women. New York City-based NEBGH is ...
- Source: drugdu
- 97
- December 6, 2023
Lilly’s Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing

As AbbVie, Johnson & Johnson, AstraZeneca and BeiGene are battling it out in the same BTK inhibitor market, Eli Lilly is trailblazing a new path for the blood cancer drug class. On Friday, Dec.1, the FDA granted accelerated approval to Lilly’s Jaypirca for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy. Jaypirca, which is itself a BTK inhibitor, is now allowed following treatment with a BTK inhibitor and a BCL-2 inhibitor. The ability to help patients who have failed on a BTK inhibitor makes Jaypirca unique. The Lilly med is a non-covalent BTK inhibitor that binds to BTK by a mechanism different from existing covalent agents, namely AbbVie/J&J’s Imbruvica, AZ’s Calquence and BeiGene’s Brukinsa. “Once patients with CLL or SLL have progressed on covalent BTK inhibitor and BCL-2 inhibitor therapies, treatments are limited and outcomes can be ...
- Source: drugdu
- 95
- December 6, 2023
Pharma industry groups push initiatives against climate change at COP28

Several pharmaceutical industry advocacy and lobby organisations have bandied together to release a joint industry statement supporting the Declaration on Climate and Health released at the ongoing COP28 meeting. The joint statement is from associations in Europe, US, Canada, and Japan, like the Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries and Associations (EFPIA), Pharmaceutical Research and Manufacturers of America (PhRMA), as well as The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) which represents over 90 pharmaceutical companies worldwide. The declaration highlights the negative impacts of climate change on health, and details objectives to ensure better health outcomes, such as implementing adaptation interventions against climate-sensitive disease and health risks. The aim of the declaration is to strengthen the implementation of policies to protect populations most vulnerable to the health impact of climate change. The COP 28 meeting is an international gathering of national leaders, regulators, ...
- Source: drugdu
- 95
- December 6, 2023
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status

By Tristan Manalac Pictured: GSK building in Poznan, Poland/iStock, Wirestock GSK CEO Emma Walmsley on Thursday touted the smooth launch of its respiratory syncytial virus vaccine Arexvy and its strong potential for growth in the coming years. In an interview with Reuters, Walmsley said the British biopharma is “delighted” with the progress it has made in the RSV vaccine race with Pfizer. “We are delighted with the start of our RSV vaccine,” Walmsley said, adding that the company expects Arexvy “will be more than £1 billion in its first year, (it) has lots of headroom for growth.” GSK is positioning Arexvy to be its next blockbuster asset. The U.S. launch of the vaccine has so far reached three million of the more than 80 million adults over 60 at risk from RSV, according to Walmsley. Arexvy became the first FDA-approved RSV shot in May 2023 and is authorized for use ...
- Source: drugdu
- 104
- December 5, 2023
Rising Cost of New Medications, Will the People Who Need Them Most be able to Afford them?

Americans can’t afford their medications. About 25% leave prescriptions unfilled, split pills, or skip doses. Seniors face challenges covering non-Medicare services, including prescriptions. Even those with commercial health insurance are not immune. One-third of insured adults worry about affording their premiums, and 44% must meet increasingly high deductibles before insurance even kicks in. As a result, 41% of adults carry substantial medical debt. At the same time, FDA approvals for therapeutics targeting rare diseases are on the rise, including those for cancer, Alzheimer’s, and many previously untreatable diseases. In fact, 54% of 2022’s novel drug approvals targeted rare diseases. They encompass groundbreaking therapies like the first acid sphingomyelinase deficiency treatment, a prurigo nodularis remedy, and an obstructive hypertrophic cardiomyopathy therapy. In 2023, the first enzyme replacement therapy for non-neurological alpha-mannosidosis effects gained early approval. Breakthroughs, though welcome, are staggeringly expensive. In fact, Hemgenix, a new treatment for hemophilia, is officially ...
- Source: drugdu
- 97
- December 5, 2023
3 Trends Employers Should Watch Out for in 2024

The top three areas of concern for employers in 2024 include rising healthcare costs, mental health challenges and cancer care, according to a recent report from Business Group on Health. By MARISSA PLESCIA There are several challenges and trends employers should keep tabs on in 2024, with rising healthcare costs topping the list, according to a report the Business Group on Health released on Tuesday. Washington, D.C.-based Business Group on Health is a non-profit organization representing large employers on health benefits and health policy issues. Here are the three top healthcare trends for employers in 2024: 1. Rising healthcare costs: Healthcare costs are expected to continue to climb in 2024 due to inflation, provider shortages, growing mental health challenges and missed preventive screenings that led to more costly health conditions. Other major cost drivers include expensive cell and gene therapies and GLP-1s. “A confluence of factors are creating a fever ...
- Source: drugdu
- 248
- December 5, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.